257 related articles for article (PubMed ID: 26869644)
1. Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?
Ansell SM
J Oncol Pract; 2016 Feb; 12(2):101-6. PubMed ID: 26869644
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
3. Targeting immune checkpoints in lymphoma.
Ansell SM
Curr Opin Hematol; 2015 Jul; 22(4):337-42. PubMed ID: 26049755
[TBL] [Abstract][Full Text] [Related]
4. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death-1 inhibition in lymphoma.
Hawkes EA; Grigg A; Chong G
Lancet Oncol; 2015 May; 16(5):e234-45. PubMed ID: 25943068
[TBL] [Abstract][Full Text] [Related]
6. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
Cheah CY; Fowler NH; Neelapu SS
Curr Opin Oncol; 2015 Sep; 27(5):384-91. PubMed ID: 26248256
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint inhibitors in Hodgkin's lymphoma.
Jezeršek Novaković B
Eur J Haematol; 2016 Apr; 96(4):335-43. PubMed ID: 26560962
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Therapy in Renal Cell Carcinoma.
Lee CH; Motzer RJ
Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
[TBL] [Abstract][Full Text] [Related]
9. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
Tsirigotis P; Savani BN; Nagler A
Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
[TBL] [Abstract][Full Text] [Related]
10. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
Bryan LJ; Gordon LI
Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
[TBL] [Abstract][Full Text] [Related]
11. PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher.
Allen PB; Gordon LI
Expert Rev Hematol; 2016 Oct; 9(10):939-49. PubMed ID: 27622603
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab in the Treatment of Hodgkin Lymphoma.
Ansell SM
Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581
[TBL] [Abstract][Full Text] [Related]
13. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
14. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid O; Carvajal RD
Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
[TBL] [Abstract][Full Text] [Related]
15. The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target.
Bardoli AD; Afshar M; Viney R; Foster M; Porfiri E; Zarkar A; Stevenson R; James ND; Bryan RT; Patel P
Future Oncol; 2016 Mar; 12(5):595-600. PubMed ID: 26880382
[No Abstract] [Full Text] [Related]
16. PD-1/PD-L1 inhibitors.
Sunshine J; Taube JM
Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of immune checkpoint inhibition in malignant lymphoma.
Hude I; Sasse S; Engert A; Bröckelmann PJ
Haematologica; 2017 Jan; 102(1):30-42. PubMed ID: 27884973
[TBL] [Abstract][Full Text] [Related]
18. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
Kerr KM; Nicolson MC
Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
[TBL] [Abstract][Full Text] [Related]
19. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
[TBL] [Abstract][Full Text] [Related]
20. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin DS; Ribas A
Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
